Key statistics dashboard for Supernus Pharmaceuticals, Inc. (SUPN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Stock Data
| Price | $43.04 |
| Market Cap | $2.5B |
| Enterprise Value | $2.34B |
| Beta | 0.73 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -22.25 |
| Price / Book | 2.41 |
| P/S | 2.99 |
| EV/EBITDA | -147.59 |
| EV/Sales | 2.82 |
| EV/FCF | 124.66 |
| P/FCF | 132.10 |
| Earnings Yield | -4.43% |
| FCF Yield | 0.76% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 88.07% |
| EBIT Margin | -14.16% |
| EBITDA Margin | -1.91% |
| Operating Margin | -13.46% |
| Net Margin | -13.23% |
| Return on Equity | -10.42% |
| Return on Assets | -7.69% |
| Return on Invested Capital | -9.12% |
| Return on Capital Employed | -10.35% |
Financial Health
| Current Ratio | 2.08 |
| Quick Ratio | 1.84 |
| Cash Ratio | 0.52 |
| Debt / Equity | 0.04 |
| Debt / Assets | 2.81% |
| Net Debt / EBITDA | 8.81 |
| Interest Coverage | -48.30 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 5.47 |
Per-Share Data
| Revenue per share | 14.30 |
| Book Value per share | 17.76 |
| Cash per share | 6.41 |
| FCF per share | 0.32 |
| Tangible Book Value per share | 7.62 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.64 |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks